Deploy predictions for H2 2026: robotaxi cities, humanoid pilots, surgical installs, trucking routes, and wearable clearances

Deploy publishes five predictions for the second half of 2026, each grounded in the current registry corpus with explicit confidence levels and cap-flags. The methodology follows the three-axis substrate framework we use for actuarial composition: each prediction reads at the lowest verification depth among its evidence axes.

Robotaxi expansion. Waymo holds active permits in California, Arizona, and Texas, with operational deployments in San Francisco, Phoenix, Los Angeles, and Austin. The registry tracks additional permit applications as pending. We predict three to five new US cities in H2 2026, with medium-high confidence, cap-flagged for regulator uncertainty. Waymo's public safety reporting provides Tier-4 stated context, while CPUC and DMV filings provide Tier-1 verification for permit status.

Humanoid logistics pilots. Verified deployments exist at GXO (Agility Digit), BMW Spartanburg (Figure 02), and a Jabil-internal pilot (Apptronik Apollo). Tesla Optimus remains at research stage with no verified commercial deployment. We predict ten to fifteen verified logistics sites by year-end, with medium confidence, cap-flagged for production capacity uncertainty. Agility's public milestone announcements and GXO operational disclosures inform the count, though neither meets Tier-1 verification for unit-level tracking.

Surgical robotics growth. Intuitive da Vinci is the only production-scale system. Stryker Mako, Zimmer Biomet ROSA, Medtronic Hugo, and Asensus Senhance have verified installations at lower volumes. We predict single-digit quarterly new-hospital growth for non-da Vinci systems, with high confidence, cap-flagged for hospital capex lag. Intuitive Surgical's investor filings provide Tier-1 verified install-base figures; competitor counts rely on Tier-4 manufacturer disclosures with broader cap-flags.

Autonomous trucking range. Bot Auto operates a verified humanless Houston-Dallas route of approximately 240 miles, documented in the registry's Bot Auto signal. No verified unsupervised route exceeds this distance in the registry. We predict no 500-mile unsupervised route in 2026, with medium-high confidence, cap-flagged for unpublicized pilot risk. Longer routes from Aurora and Kodiak remain at stated or claimed posture without verified operator disclosure.

Wearable FDA clearance. Oura holds FDA clearance for certain features. RingConn, Ultrahuman, and Amazfit are expanding into health-adjacent features. We predict at least one novel 510(k) clearance in the wearable or biometric category in H2 2026, with medium confidence, cap-flagged for FDA timeline opacity. The FDA medical devices page provides Tier-1 verification for existing clearances; future submissions are invisible until posted.